Design of phase III trials with long-term survival outcomes based on short-term binary results

Marta Bofill Roig, Yu Shen, Guadalupe Gómez Melis

Pathologic complete response (pCR) is a common primary endpoint for a phase II trial or even accelerated approval of neoadjuvant cancer therapy. If granted, a two-arm confirmatory…